GALR3

Galanin receptor type 3 · O60755 · GALR3 on Sugi Atlas →

44,566 patent compounds predicted against GALR3, 24,904 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Chlormidazole (SCHEMBL148113)	1.00	3/20
Chlormidazole (SCHEMBL364033)	0.97	3/20
SCHEMBL231295	0.79	3/20
SCHEMBL350954	0.52	3/20
SCHEMBL369182	0.47	3/20
SCHEMBL374825	0.47	3/20
SCHEMBL204650	0.39	3/20
SCHEMBL139931	0.38	3/20
SCHEMBL204360	0.33	3/20
Methacholine (SCHEMBL69104)	1.00	2/20
Acetylcholine (SCHEMBL317763)	1.00	2/20
Methacholine (SCHEMBL69103)	0.95	2/20
Acetylcholine (SCHEMBL3216)	0.95	2/20
Methacholine (SCHEMBL424740)	0.91	2/20
Acetylcholine (SCHEMBL40885)	0.91	2/20
Rotenone (SCHEMBL42253)	0.71	2/20
Amorphigenin (SCHEMBL74859)	0.68	2/20
Amorphigenin (SCHEMBL74860)	0.68	2/20
SCHEMBL119825	0.65	2/20
SCHEMBL168409	0.64	2/20

Clinical trials — most relevant to GALR3 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Investigating the Potential Role of Aerosolized Retinoic Acid, a Potent Vitamin A Metabolite for Treating COVID-19 Anosmia and Retinoic Acid Insufficiency .A Novel Approach for Regaining Sense of Smell.	PHASE4	UNKNOWN
Effects of Genotype on Resting State Connectivity During Methamphetamine Administration	PHASE4	COMPLETED
Medication, Weight Gain and GI Hormones	PHASE4	COMPLETED
Once Daily Long-Acting Muscarinic Antagonists Administered in the Evening for Prevention of Chronic Obstructive Pulmonary Disease Exacerbations Requiring Hospitalization or Death from Any Cause	PHASE4	COMPLETED
Lemborexant Augmentation of Naltrexone for Alcohol Craving and Sleep	PHASE3	COMPLETED
A Phase 1/2 Study of Intravenous Gene Transfer With an AAV9 Vector Expressing Human Beta-galactosidase in Type I and Type II GM1 Gangliosidosis	PHASE1/PHASE2	RECRUITING
Carbidopa-levodopa in Neovascular AMD	PHASE2	COMPLETED
A Series of Pilot Studies to Evaluate the haemoDynamic and mEtabolic Effects oF apelIn aNd rElaxin	PHASE2	UNKNOWN
Varenicline (Chantix™) for the Treatment of Alcohol Dependence	PHASE2	COMPLETED
Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma	PHASE2	RECRUITING
Effect of Continuous GHRP-3 Infusion at on GH-IGF-I System, Blood Pressure, Glucose, and Insulin Resistance	PHASE1/PHASE2	WITHDRAWN
Comparative Study to Test Safety and Efficacy of Neurotrophic and Cholinergic Treatment of Alzheimer's Disease	PHASE2	COMPLETED
Studying the Influence of LEAP2 on Integrated Endocrine Control of Eating During Semaglutide Treatment	PHASE1/PHASE2	RECRUITING
Role of the Gut Sweet Taste Receptor in the Secretion of Satiation Peptides	PHASE1	COMPLETED
Sweet Taste Receptors and the Secretion of Glucagon-like Peptide-1 and Peptide YY	PHASE1	COMPLETED
Brain Networks and Addiction Susceptibility	PHASE1	COMPLETED
Longitudinal Analysis of Amylin Levels in Migraine Patients Undergoing an Anti- CGRP/CGRPr Treatment	nan	NOT_YET_RECRUITING
In Vitro Studies on Pharmacological Regulation and Genetic Risk Factors of Peripheral Human Nociceptors	nan	COMPLETED
Krabbe Disease Global Patient Registry	nan	RECRUITING
A Combined Psycho-pharmacological and Brain Imaging Study of Human Sexuality	nan	SUSPENDED
Insulin Detemir in Obesity Management	nan	ACTIVE_NOT_RECRUITING
Brain-Derived Neurotrophic Factor in Obesity and Brain Function	nan	COMPLETED
Sexually Dimorphic Effects of GHRH in Adult Growth Hormone Testing	nan	COMPLETED
Brain Receptors in Sympathetic Nervous System Regulation	nan	COMPLETED
Auricular Vagus Stimulation in Obesity	nan	ACTIVE_NOT_RECRUITING
Precision Obesity Medicine: Genetic Prediction of Response to GLP-1/GIP Agonists.	nan	RECRUITING
Glycosylation in Patients With Galactosaemia	nan	COMPLETED
The Role of Autoantibodies Against G-protein Coupled Receptors in Obesity	nan	NOT_YET_RECRUITING
Psychology of Reward and Punishment: Functional and Molecular Brain Imaging and Monoaminergic Correlates	nan	WITHDRAWN
BIOmarkers of MIGraine: a Proof of Concept Study Based on the Stratification of Responders to CGRP Monoclonal Antibodies	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a GALR3 binder may also engage these)

Protein	Name	Similarity
O88626	—	0.998	O88626 →
O88853	—	0.994	O88853 →
GALR2	Galanin receptor type 2	0.981	landscape →
O00155	—	0.977	O00155 →
Q6TLJ0	—	0.976	Q6TLJ0 →
Q8HYC3	—	0.973	Q8HYC3 →
Q60483	—	0.972	Q60483 →
P0C5I1	—	0.971	P0C5I1 →
O88854	—	0.970	O88854 →
O08726	—	0.970	O08726 →
ADRB3	Beta-3 adrenergic receptor	0.969	landscape →
UTS2R	Urotensin-2 receptor	0.967	landscape →
P30935	—	0.967	P30935 →
P30936	—	0.967	P30936 →
KISS1R	KiSS-1 receptor	0.966	landscape →
HTR6	5-hydroxytryptamine receptor 6	0.966	landscape →
RXFP4	Relaxin-3 receptor 2	0.964	landscape →
Q8MJV3	—	0.964	Q8MJV3 →
DRD4	D(4) dopamine receptor	0.964	landscape →
P51436	—	0.964	P51436 →
AVPR2	Vasopressin V2 receptor	0.963	landscape →
Q28524	—	0.962	Q28524 →
Q96P69	—	0.962	Q96P69 →
Q95252	—	0.962	Q95252 →
CCR10	C-C chemokine receptor type 10	0.961	landscape →
O02662	—	0.961	O02662 →
P31388	—	0.959	P31388 →
Q9XT58	—	0.959	Q9XT58 →
Q5IS65	—	0.959	Q5IS65 →
P30729	—	0.959	P30729 →